Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study.
Hess A, Tascilar K, Schenker HM, Konerth L, Schönau V, Sergeeva M, Kreitz S, Prade J, Strobelt S, Selvakumar M, Kleyer A, Englbrecht M, Hueber AJ, Zaiss MM, Feist E, Burmester GR, Voll RE, Finzel S, Baerwald C, Rösch J, Behrens F, Koehm M, da Silva JAP, Damjanov N, Dörfler A, Schett G, Rech J.
Hess A, et al. Among authors: feist e.
Lancet Rheumatol. 2025 Aug;7(8):e565-e575. doi: 10.1016/S2665-9913(25)00032-3. Epub 2025 Jun 23.
Lancet Rheumatol. 2025.
PMID: 40570879
Free article.
Clinical Trial.